Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure

M Tang, G Wang, P Lu, RH Karas, M Aronovitz… - Nature medicine, 2003 - nature.com
M Tang, G Wang, P Lu, RH Karas, M Aronovitz, SP Heximer, KM Kaltenbronn, KJ Blumer
Nature medicine, 2003nature.com
Nitric oxide (NO) inhibits vascular contraction by activating cGMP-dependent protein kinase I-
α (PKGI-α), which causes dephosphorylation of myosin light chain (MLC) and vascular
smooth muscle relaxation. Here we show that PKGI-α attenuates signaling by the thrombin
receptor protease-activated receptor-1 (PAR-1) through direct activation of regulator of G-
protein signaling-2 (RGS-2). NO donors and cGMP cause cGMP-mediated inhibition of PAR-
1 and membrane localization of RGS-2. PKGI-α binds directly to and phosphorylates RGS-2 …
Abstract
Nitric oxide (NO) inhibits vascular contraction by activating cGMP-dependent protein kinase I-α (PKGI-α), which causes dephosphorylation of myosin light chain (MLC) and vascular smooth muscle relaxation. Here we show that PKGI-α attenuates signaling by the thrombin receptor protease-activated receptor-1 (PAR-1) through direct activation of regulator of G-protein signaling-2 (RGS-2). NO donors and cGMP cause cGMP-mediated inhibition of PAR-1 and membrane localization of RGS-2. PKGI-α binds directly to and phosphorylates RGS-2, which significantly increases GTPase activity of Gq, terminating PAR-1 signaling. Disruption of the RGS-2–PKGI-α interaction reverses inhibition of PAR-1 signaling by nitrovasodilators and cGMP. Rgs2−/− mice develop marked hypertension, and their blood vessels show enhanced contraction and decreased cGMP-mediated relaxation. Thus, PKGI-α binds to, phosphorylates and activates RGS-2, attenuating receptor-mediated vascular contraction. Our study shows that RGS-2 is required for normal vascular function and blood pressure and is a new drug development target for hypertension.
nature.com